$$\rightleftharpoonup{xx}$$
$$\longleftharp{xx}$$,
$$\longrightharp{xx}$$,
The ECM serves as a scaffold for cells, supporting them through an intricate architecture maintained by different components, and it is one of the major factors responsible for the mechanical properties of the heart and cardiac tissue function1,2. Increasing evidence suggests that ECM plays an active role in tissue remodeling, making the conventional assumption that the ECM is a passive component obsolete3,4,5,6. The role of the ECM is to provide biophysical and biochemical cues to resident cells. It is well-established that these signals can influence many fundamental cell behaviors, impacting their contractile function, proliferation, migration, and differentiation potential7,8,9. Thus, ECM is increasingly being employed in tissue engineering and regenerative medicine as a therapeutic support tool9,10,11,12,13.
The ECM consists of several proteins such as collagen, elastin, fibronectin, proteoglycan, and laminin, along with ECM-bound growth factors, all involved in regeneration mechanisms, such as cell recruitment, migration, and differentiation, as well as cell alignment and proliferation14. The mechanical properties of the tissues also have great relevance in the physiopathology of the organs. Indeed, changes in mechanical properties are often associated with the onset and the evolution of several diseases. The reason resides in the fact that when the ECM is modified, signals coming from the environment induce changes in gene and protein expression, leading to functional impairment15,16.
Regenerative therapies for organ repair are currently focused on replicating the sophisticated microenvironment of the native tissue to heal the organ where the body fails. Despite the rapid pace of many tissue engineering approaches, the tissues still cannot be reproduced accurately in their entirety and complexity by artificial procedures. Synthetic materials have been largely employed so far, as they can be appropriately tuned to simulate the mechanical and biochemical properties of the cellular microenvironment. Nevertheless, they have limits, such as the inability to mimic the numerous interactions within the native tissue, the cost of technologies to produce them, and the fact that they are less natural and biocompatible than native tissue17,18,19. Additionally, their composition, primarily in terms of proteins and soluble factors, greatly differs from the natural one, which is extremely difficult to replicate20.
The cutting-edge approach in regenerative medicine to reduce the gap between the patients in need and organ transplants is to produce scaffolds made of decellularized extracellular matrix (d-ECM) and repopulate them with the appropriate cell types to regenerate the damaged organs. Decellularization is the process in which the ECM is isolated from its native cells and genetic material to produce a natural and biomimetic scaffold, able to avoid the immune response and rejection once implanted in the patients21,22,23. The ECM thus obtained can then be repopulated to produce functional tissue. The major issue when developing a d-ECM is the method. For any decellularization technique, the primary goal remains the preservation of the native ECM composition, stiffness, and 3D structure, and all strategies have both benefits and drawbacks. Because the elimination of cellular content and DNA from the tissue requires the use of chemical or physical agents, or the combination of both, each decellularization procedure causes, to different degrees, the disruption of the ECM. Hence, it is crucial to minimize the damage to the ECM24,25,26.
Native ECM utilization as a platform for the reconstitution of native ECM in vitro is highly desirable. For this purpose, several decellularization protocols have been applied to a wide range of tissues27,28,29,30. In fact, since the early stages of decellularization research and ECM development, several tissues, such as arteries, aortic valves, and peripheral nerves from both animals and humans, have been decellularized, and some d-ECMs are still commercially available and used for tissue replacement or wound healing31,32,33. Recently, human skin has also emerged as a suitable candidate to produce decellularized scaffolds for cardiac repair owing to its composition and mechanical properties-able to boost the regenerative potential of cardiac progenitor cells (CPCs) and adapt to cardiac contractility34. This paper describes a simple and fast protocol to produce decellularized scaffolds from adult human skin, allowing the development of a d-ECM with well-preserved architecture.